Journal of thrombosis and haemostasis : JTH · 2026
Safety and Emergency Dose Response Evaluation of Lyophilized Synthetic Platelets in a Rat Model of Traumatic Hemorrhage.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luc Norman F, Disharoon Dante, Hernandez Selvin, Singh Sekhon Ujjal Didar, Traylor Baylee, Gahagan Emily, Quill Emma, Aldridge Kristin, Bruckman Michael A, Pawlowski Christa L, Gupta Anirban Sen
Аннотация
BACKGROUND: Early hemostatic resuscitation with platelets can significantly improve survival in hemorhaging patients. Here, platelet-mimicking technologies can serve as surrogates when donor-derived platelets are unavailable. We have developed a synthetic platelet technology (SynthoPlate, SP) that mimics platelet's primary hemostatic mechanisms, and have previously reported its efficacy. Recently we have advanced SP into a lyophilized product (Lyo-SP) that preserves functional equivalence to SP while allowing long shelf-life, easy portability, and rapid reconstitution for on-demand use.
OBJECTIVE: We evaluated Lyo-SP in an emergency setting in a rat model of liver injury hemorrhage.
METHODS: First, Lyo-SP was tested ex vivo in two complementary microfluidic assays (BioFlux and T-TAS) to establish functionality in rat blood. Subsequently, Lyo-SP was administered in rats at escalating doses to determine safety. Finally, Lyo-SP hemostatic efficacy was evaluated in the rat liver hemorrhage model, given at two different doses at two different time-points post-injury, simulating emergency treatment.
RESULTS: Ex vivo, Lyo-SP demonstrated significant hemostatic capability in a rat blood-based hemodilution model. In vivo, Lyo-SP was well-tolerated in rats up to 20 mg/kg and showed no clotting risks in clearance organs, confirmed by histology. In the liver hemorrhage model, rats dosed with 0.5 mg/kg Lyo-SP immediately (∼1-min) or at 5-min post-injury minimally reduced blood loss and mortality compared to controls. In contrast, rats dosed with 5 mg/kg Lyo-SP immediately (∼1-min) or at 5-min post-injury significantly reduced blood loss and mortality.
CONCLUSIONS: The results indicate significant promise of Lyo-SP as an on-demand therapy for emergency management of hemorrhage to improve survival.
OBJECTIVE: We evaluated Lyo-SP in an emergency setting in a rat model of liver injury hemorrhage.
METHODS: First, Lyo-SP was tested ex vivo in two complementary microfluidic assays (BioFlux and T-TAS) to establish functionality in rat blood. Subsequently, Lyo-SP was administered in rats at escalating doses to determine safety. Finally, Lyo-SP hemostatic efficacy was evaluated in the rat liver hemorrhage model, given at two different doses at two different time-points post-injury, simulating emergency treatment.
RESULTS: Ex vivo, Lyo-SP demonstrated significant hemostatic capability in a rat blood-based hemodilution model. In vivo, Lyo-SP was well-tolerated in rats up to 20 mg/kg and showed no clotting risks in clearance organs, confirmed by histology. In the liver hemorrhage model, rats dosed with 0.5 mg/kg Lyo-SP immediately (∼1-min) or at 5-min post-injury minimally reduced blood loss and mortality compared to controls. In contrast, rats dosed with 5 mg/kg Lyo-SP immediately (∼1-min) or at 5-min post-injury significantly reduced blood loss and mortality.
CONCLUSIONS: The results indicate significant promise of Lyo-SP as an on-demand therapy for emergency management of hemorrhage to improve survival.